Patent Battles in India: Innovation vs. Access
How Pharmaceutical Litigation Shapes Public Health
Lessons from Novartis, Compulsory Licensing, and Global Comparisons
By Vishwas Kumar
New Delhi: June 20, 2026:
Patent law in India sits at the delicate intersection of innovation and public welfare. The Patents Act, 1970, substantially amended in 2005 to align with the WTO’s TRIPS Agreement, provides the framework for protecting inventions. While patents grant inventors exclusive rights for 20 years, incentivizing research and development, they also raise pressing concerns about affordability—particularly in pharmaceuticals, where life-saving drugs can become prohibitively expensive for the majority of patients.
To understand the constitutional guarantee of equality before law and equal protection of laws, readers can explore our detailed guide on Article 14 of the Constitution of India . This article explains important Supreme Court interpretations, landmark judgments, and how Article 14 protects citizens against arbitrary state action, making it one of the most fundamental rights under the Indian Constitution.
India’s judiciary has repeatedly confronted this tension between monopoly rights and public health. The Novartis AG v. Union of India (2013) case remains emblematic. Novartis sought a patent for its cancer drug Glivec, but the Supreme Court denied protection, ruling that incremental innovation without demonstrable therapeutic efficacy does not qualify under Section 3(d). This landmark decision reinforced India’s stance against “evergreening,” a practice where pharmaceutical companies attempt to extend patent monopolies through minor modifications. The ruling was celebrated globally as a victory for access to affordable medicines, though it also sparked debate about whether India’s strict standards discourage foreign investment in innovation.
Another milestone was the Natco Pharma v. Bayer (2012) compulsory licensing case. The Controller General of Patents granted Natco permission to produce a generic version of Bayer’s cancer drug Sorafenib, citing unaffordable pricing and insufficient availability. This was India’s first compulsory license, and it highlighted the country’s commitment to balancing intellectual property rights with constitutional obligations to protect public health.
Together, these cases illustrate India’s broader policy choice: patents must reward genuine innovation but cannot be allowed to undermine access to essential medicines. As India navigates global trade obligations, domestic healthcare priorities, and the demands of a growing pharmaceutical industry, patent litigation continues to serve as a battleground where innovation, affordability, and human rights converge.
Key Legal Provisions – Analytical Narrative
The Patents Act, 1970, as amended in 2005 to comply with TRIPS, provides the statutory framework for patent protection in India. Its provisions reflect a deliberate balance between incentivizing innovation and safeguarding public health, particularly in the pharmaceutical sector.
At the heart of this balance is Section 3(d), which prevents patents for new forms of known substances unless they demonstrate enhanced therapeutic efficacy. This clause was pivotal in the Novartis v. Union of India case, where the Supreme Court denied a patent for Glivec, ruling that incremental changes without significant medical benefit do not merit monopoly rights. Section 3(d) thus acts as a safeguard against “evergreening,” ensuring patents reward genuine innovation rather than minor modifications.
Section 48 grants patentees exclusive rights to make, use, and sell their inventions, forming the basis of patent enforcement. However, these rights are tempered by Section 83, which emphasizes that patents must work for the public good, promoting access and affordability. This provision reflects India’s constitutional commitment to health and welfare.
Section 84 governs compulsory licensing, allowing third parties to produce patented drugs if they are not reasonably affordable or sufficiently available. The Natco v. Bayer case exemplified this, where Natco was granted a license to produce a generic cancer drug at a fraction of Bayer’s price.
Additionally, Section 107A, known as the Bolar exemption, permits generic manufacturers to use patented inventions for regulatory approval before the patent expires. This ensures that affordable alternatives can enter the market promptly once exclusivity ends.
Together, these provisions illustrate India’s unique approach: patents are recognized as vital for innovation, but they cannot override the imperative of public health. By embedding safeguards like Section 3(d) and compulsory licensing, the law ensures that intellectual property serves both inventors and society.
Judicial Reasoning – Analytical Narrative
Indian courts have consistently approached patent disputes through the lens of public interest, recognizing that intellectual property rights must coexist with constitutional commitments to health and welfare. Judicial reasoning in landmark cases reflects a philosophy that patents are not absolute monopolies but conditional rights, granted only when they serve genuine innovation and societal benefit.
The Novartis AG v. Union of India (2013) case is the most prominent example. Novartis sought a patent for its cancer drug Glivec, arguing that its beta crystalline form represented an inventive step. The Supreme Court, however, interpreted Section 3(d) strictly, ruling that incremental innovation without demonstrable therapeutic efficacy does not qualify for patent protection. The Court reasoned that granting such patents would encourage “evergreening,” undermining access to affordable medicines. This judgment reinforced the principle that patents must reward substantive innovation, not minor modifications designed to extend monopolies.
In Natco Pharma v. Bayer (2012), the Controller General of Patents granted India’s first compulsory license under Section 84, allowing Natco to produce a generic version of Bayer’s cancer drug Sorafenib. The reasoning was rooted in affordability and availability: Bayer’s drug was priced beyond the reach of most patients and insufficiently supplied in India. The decision highlighted that patent rights cannot be exercised in a manner that denies access to essential medicines, especially when public health is at stake.
The Roche v. Cipla (2009) case further illustrated this balance. The Delhi High Court refused to grant an injunction against Cipla’s generic version of Roche’s cancer drug, emphasizing that public interest in affordable medicines outweighed Roche’s exclusivity claims. The Court acknowledged the importance of patents but prioritized patient access in life-saving contexts.
Judicial reasoning in these cases consistently invokes Section 83, which frames patents as instruments of public good. Courts emphasize that intellectual property must serve society, not merely corporate profits. This approach distinguishes India from jurisdictions that prioritize exclusivity, positioning Indian jurisprudence as a model for balancing innovation with access.
Ultimately, Indian courts have crafted a pragmatic philosophy: patents are vital for encouraging research, but they cannot override the fundamental right to health. By interpreting provisions like Section 3(d) and compulsory licensing in favor of public interest, the judiciary ensures that patent law remains aligned with India’s democratic and humanitarian values.
Comparative Perspectives – Analytical Narrative
India’s approach to patent law, particularly in pharmaceuticals, stands out globally for its emphasis on public health over monopoly rights. While most jurisdictions prioritize strong patent protection to incentivize innovation, India has deliberately crafted safeguards to prevent abuse and ensure access to essential medicines.
In the United States, patent protection is robust under the Hatch-Waxman Act. The law encourages innovation by granting exclusivity periods and allowing patent extensions through supplementary certificates. However, critics argue that this framework contributes to high drug prices, with limited mechanisms to counter evergreening. The US courts generally favor patentees, emphasizing innovation incentives over affordability.
The European Union adopts a more balanced stance. While patents are strongly protected, the EU imposes stricter scrutiny on incremental innovations and provides supplementary protection certificates to extend patent life only in specific circumstances. The EU also recognizes the importance of competition law in curbing abuse of patent monopolies, reflecting a nuanced balance between innovation and consumer welfare.
India diverges sharply with its Section 3(d), which explicitly bars patents for minor modifications unless they enhance therapeutic efficacy. This provision, unique to India, was pivotal in the Novartis case and has become a global reference point for resisting evergreening. Additionally, India’s use of compulsory licensing under Section 84, as seen in Natco v. Bayer, demonstrates a willingness to override exclusivity when public health demands it.
Developing countries often look to India’s model as a precedent. Nations in Africa and Asia cite India’s jurisprudence to justify compulsory licensing and stricter patent standards, arguing that TRIPS allows flexibility for public health. India’s stance has thus become emblematic of a “development-oriented” approach to intellectual property.
In sum, while the US and EU emphasize innovation incentives, India prioritizes access and affordability, embedding public interest directly into its patent framework. This divergence highlights India’s unique role in shaping global debates on intellectual property and healthcare, positioning it as a leader in balancing innovation with human rights.
Case Studies
Novartis v. Union of India (2013): Denial of patent for Glivec, landmark against evergreening.
Natco v. Bayer (2012): First compulsory license in India, enabling affordable generics.
Roche v. Cipla (2009): Delhi High Court allowed generics for cancer drug, prioritizing affordability.
Gilead’s Sofosbuvir licensing (2014): Voluntary licenses to Indian firms, showing collaborative models.
These cases illustrate India’s pragmatic balance between innovation and access.
Extended FAQ – Patent Law & Pharma Litigation
What is a patent? A legal right granting inventors exclusive use of their invention for 20 years.
What is Section 3(d)? It bars patents for new forms of known substances unless they show enhanced efficacy.
What is compulsory licensing? Authorization for a third party to produce a patented product when it’s unaffordable or unavailable.
What did the Novartis case decide? The Supreme Court denied a patent for Glivec, preventing “evergreening.”
What did Natco v. Bayer decide? India’s first compulsory license, allowing Natco to produce a generic cancer drug.
What is evergreening? Extending patent monopolies through minor modifications without real innovation.
What is Section 83? It states patents must balance rights with public interest.
What is Section 48? It grants patentees exclusive rights to prevent unauthorized use.
What is Section 107A? The “Bolar exemption,” allowing generics to use patents for regulatory approval.
How long do patents last? 20 years from the date of filing.
What is therapeutic efficacy? Improved medical effectiveness required for patenting under Section 3(d).
What is the TRIPS Agreement? A WTO treaty requiring minimum IP standards, including patents.
How did India comply with TRIPS? By amending the Patents Act in 2005 to allow pharma product patents.
What is the Novartis Glivec dispute? A battle over whether incremental innovation deserved patent protection.
What is the Natco compulsory license? Permission to produce Bayer’s drug at affordable prices.
What is the Roche v. Cipla case? Delhi High Court allowed generics for cancer drug, prioritizing affordability.
What is the Bolar exemption’s purpose? To let generics prepare for market entry once patents expire.
What is Section 84? It governs compulsory licensing, ensuring access to essential medicines.
What is patent infringement? Unauthorized use of a patented invention.
What remedies exist for infringement? Injunctions, damages, and account of profits.
What is patent opposition? A process to challenge patents before or after grant.
What is pre-grant opposition? Objection filed before a patent is granted.
What is post-grant opposition? Objection filed within one year after grant.
What is Section 3(b)? Excludes inventions contrary to public order or morality.
What is Section 3(i)? Excludes methods of treatment from patentability.
What is Section 3(k)? Excludes computer programs per se from patents.
What is Section 3(p)? Excludes traditional knowledge from patentability.
What is patent licensing? Permission granted by the patentee to another party to use the invention.
What is voluntary licensing? Agreements where patentees allow generics to produce drugs.
What is patent pooling? Multiple patentees combine rights to facilitate innovation.
What is patent litigation? Court disputes over validity or infringement of patents.
What is patent revocation? Cancellation of a patent due to invalidity or non-compliance.
What is Section 64? Lists grounds for revocation of patents.
What is Section 66? Allows revocation if patents are prejudicial to public interest.
What is patent examination? Scrutiny by the Patent Office before grant.
What is patent prosecution? The process of applying for and securing a patent.
What is patent specification? A detailed description of the invention filed with the application.
What is patent claim? Defines the scope of protection sought.
What is patentability criteria? Novelty, inventive step, and industrial applicability.
How does India’s approach differ globally? India prioritizes access and affordability, unlike US/EU which emphasize exclusivity.
Op-Ed Closing Vision
Patent law in India is not just about protecting innovation—it is about safeguarding lives. The Novartis and Natco cases show India’s willingness to challenge global pharmaceutical giants in favor of public health. While critics argue this discourages investment, supporters see it as a moral stance: no monopoly should deny access to essential medicines.
As India’s pharmaceutical industry grows, the challenge will be to balance incentives for innovation with affordability. Voluntary licensing, collaborative R&D, and global partnerships may offer middle paths. Ultimately, India’s patent jurisprudence reflects its democratic ethos: innovation must serve society, not just shareholders.